{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:31:25Z","timestamp":1793194285415,"version":"4.5.0"},"reference-count":0,"publisher":"American Society of Hematology","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Talquetamab is the first and only approved bispecific antibody targeting G protein-coupled receptor class C group 5 member D (GPRC5D) for treatment of relapsed\/refractory multiple myeloma based on results from the phase 1\/2 MonumenTAL-1 study. Here, we report efficacy and ongoing safety from MonumenTAL-1 with 3 years of follow-up. Patients na\u00efve to T-cell redirection therapy (TCR) received talquetamab 0.4 mg\/kg weekly (n=143) or 0.8 mg\/kg every other week (n=154); a separate cohort received prior TCR (n=78, either talquetamab dose). Median follow-up was 38, 31, and 30 months in the 3 cohorts, respectively, as of September 2024. Overall response rate was 67-74% and complete response or better rate was 33-42%. Median progression-free survival was 7.5, 11.2, and 7.7 months, and median overall survival (OS) was 34.0 months, not reached, and 28.3 months (36-month OS rates 49.3%, 60.8%, and 44.6%), in the 3 cohorts, respectively. The most common adverse events (AEs) were cytokine release syndrome (73-79%; grade 3\/4, 0.6-2.1%), taste changes (72-76%), and infections (61-78%; grade 3\/4, 21-26%). Ataxia\/balance disorders occurred in 5.3% of patients (no grade 4\/5 events). Dose reduction and discontinuation rates due to AEs remained low; no patients died due to talquetamab-related AEs. With 3 years of follow-up, talquetamab continued to demonstrate high rates of deep and durable responses. The long-term safety profile was comparable to previous results and continued to show lower risk of high-grade infections relative to approved BCMA-targeting bispecific antibodies. NCT03399799 (phase 1) and NCT04634552 (phase 2)<\/jats:p>","DOI":"10.1182\/blood.2025031994","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:20:10Z","timestamp":1786044010000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Talquetamab in patients with relapsed\/refractory multiple myeloma: 3-year follow-up of the phase 1\/2 MonumenTAL-1 study"],"prefix":"10.1182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"first","affiliation":[{"name":"University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"name":"University hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C","family":"Minnema","sequence":"additional","affiliation":[{"name":"UMC Utrecht, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1251-4649","authenticated-orcid":false,"given":"Niels","family":"van de Donk","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[{"name":"Cancer Center Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Instituto de Biologia Molecular y Celular del Cancer (Universidad de Salamanca-Consejo Superior de Investigacion, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Christine","family":"Ye","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, Texas, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4322-930X","authenticated-orcid":false,"given":"Chalmer","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, San Diego, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrajeet","family":"Singh","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Qin","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Campagna","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Masterson","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Vreys","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie W","family":"Lau","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Raritan, New Jersey, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaszianne","family":"Tolbert","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Raritan, New Jersey, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,6]]},"container-title":["Blood Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025031994\/2536975\/blood.2025031994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025031994\/2536975\/blood.2025031994.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:20:11Z","timestamp":1786044011000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/doi\/10.1182\/blood.2025031994\/570026\/Talquetamab-in-patients-with-relapsed-refractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/blood.2025031994","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"blood.2025031994"}}